Weekly News Recap #Phispers | PharmaCompass.com

Consortium makes ~US$ 3 bn offer to buy Bavarian Nordic; FDA approves PTC’s rare genetic disorder drug

The US Food and Drug Administration (FDA) has approved PTC Therapeutics’ oral drug to treat a rare genetic disorder known...

Impressions : 663

Astra to invest US$ 50 bn in US to avoid tariffs; Dr. Reddy’s to launch generic Wegovy in 87 countries next year

AstraZeneca and Biogen are the latest drugmakers to announce investments in the US to avoid import tariffs. AstraZeneca is in...

Impressions : 1057

Sarepta lays off 500 employees post second death in Elevidys trial; FDA chief proposes lowering PDUFA fee

This week’s Phispers brings you updates on cell and gene therapies (CGTs). After the death of a second teenaged boy last ...

Impressions : 4168

Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal

The world of pharmaceuticals continued to witness large deals. Merck announced a US$ 10 billion acquisition of Verona Pharma, g...

Impressions : 581

AbbVie doubles down on immunology with US$ 2.1 bn Capstan buyout; India’s Torrent buys controlling stake in JB Chem

This week in Phispers, AbbVie struck a deal worth up to US$ 2.1 billion to acquire Capstan Therapeutics and its innovative in v...

Impressions : 651

Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer

In news this week, Royalty Pharma committed up to US$ 2 billion to Revolution Medicines for their promising pancreatic and lung...

Impressions : 2969

Lilly acquires gene-editing firm Verve for US$ 1.3 bn, BioNTech buys CureVac; Astra signs US$ 5.3 bn AI deal with China’s CSPC

This week’s Phispers comes with news on several M&A deals. Eli Lilly made headlines with its US$ 1.3 billion acquisition ...

Impressions : 618

RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials

This week, US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. dismissed all 17 members of the US Centers for D...

Impressions : 1084

BMS partners BioNTech in US$ 11 bn cancer drug deal; Sanofi to acquire Blueprint Medicines for US$ 9.5 bn

The pharmaceutical sector saw several significant deals with major players expanding their portfolios. Bristol Myers Squibb (BM...

Impressions : 562

Lilly expands pain pipeline via US$ 1 bn SiteOne buyout; US cancels funding for Moderna’s bird flu vaccine

In news this week, Eli Lilly has placed a billion-dollar bet on non-opioid pain management by acquiring SiteOne Therapeutics fo...

Impressions : 688

Pfizer inks US$ 6 bn oncology deal with China’s 3SBio; BioNTech to invest US$ 1.3 bn in UK for new R&D, AI centers

In news this week, Pfizer announced a US$ 6 billion licensing agreement with China’s 3SBio, securing global rights to a p...

Impressions : 699

Trump signs ‘most favored nation’ executive order to slash drug costs; Sanofi, Takeda pledge mega investments in US

The US President Donald Trump’s dramatic intervention in pharmaceutical pricing took centerstage as the White House unvei...

Impressions : 770

BMS to invest US$ 40 bn to boost US manufacturing, R&D; 19 states sue Trump admin for gutting health agencies

US President Donald Trump’s tariff threats appear to be working, as Bristol Myers Squibb became the latest drugmaker to a...

Impressions : 1685

AbbVie, Amgen, Thermo Fisher to invest in US manufacturing to avoid tariffs; Merck KGaA acquires SpringWorks for US$ 3.9 bn

Ever since US President Donald Trump has talked about a “major tariff” on drug imports coming “very shortly&r...

Impressions : 899

Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm

After Eli Lilly, Johnson & Johnson and Novartis, Roche has announced plans to manufacture in the US to avoid tariffs. The Swiss...

Impressions : 1067

Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill

After Eli Lilly and Johnson & Johnson, Novartis has become the latest big pharma to announce mega investments in the US. The ...

Impressions : 968

Pharma tariffs coming soon, warns Trump; GSK, Lilly ink billion-dollar deals for blood-brain barrier technology

In this week’s news, US President Donald Trump has said “major” pharmaceutical import tariffs are coming soon...

Impressions : 1113

CBER director forced out in FDA gutting; Sanofi, Alnylam’s RNAi therapy Qfitlia wins US approval for hemophilia A, B

The pharma industry saw its most tumultuous week in the recent past with the US Food and Drug Administration (FDA) facing an un...

Impressions : 1009

J&J plans US$ 55 bn investment in US to avoid Trump’s tariffs; Astra to invest US$ 2.5 bn in Chinese R&D centre

This week’s Phispers brings you lots of news from China. AstraZeneca is investing US$ 2.5 billion in a new Beijing resear...

Impressions : 904

Mallinckrodt, Endo merge in US$ 6.7 bn deal; Astra buys cell therapy developer EsoBiotec; Pfizer sells entire stake in Haleon

In Phispers this week, two drugmakers emerging from bankruptcy — Mallinckrodt and Endo — are merging in order to le...

Impressions : 1190

Roche buys rights to Zealand’s obesity med in US$ 5.3 bn deal; Merck wins Gardasil lawsuit, bolsters vaccine manufacturing

In news this week, Roche has acquired rights to develop and commercialize Zealand Pharma’s experimental obesity drug petr...

Impressions : 1245

AbbVie enters obesity race with US$ 2.23 bn deal with Denmark’s Gubra; Roche’s TNKase approved for treating strokes

AbbVie has forayed into the obesity treatment market with a US$ 2.23 billion licensing deal with Denmark’s Gubra for its ...

Impressions : 958

Lilly to invest US$ 27 bn in US as Trump threatens big pharma with tariffs; FDA scrambles to rehire after mass layoffs

In the US, President Donald Trump has been putting pressure on Big Pharma to reshore or face tariffs. Eli Lilly has been the ...

Impressions : 1058

US health agencies brace for more layoffs under RFK Jr; Novo alleges fraud in US$ 1.3 bn deal with KBP BioSciences

In this week’s Phispers, we bring you news from the public health agencies in the US that have already witnessed consider...

Impressions : 961

Bain buys Mitsubishi Tanabe for US$ 3.4 bn, Novartis acquires Anthos for US$ 3.1 bn, FDA okays AbbVie-Pfizer’s new antibiotic

In this week’s news, Bain Capital acquired Japanese pharma Mitsubishi Tanabe for US$ 3.4 billion. And Novartis acquired B...

Impressions : 1690

FDA okays Vertex’s non-opioid painkiller, Supernus’ wearable device for Parkinson’s; Sanofi, GSK plan share buybacks

While the healthcare sector in the US was embroiled in political uncertainties over tariffs and key appointments, the country&r...

Impressions : 713

FDA approves Ozempic to treat CKD in diabetes patients; AbbVie, Neomorph ink US$ 1.64 bn deal for molecular glue degraders

Novo Nordisk’s Ozempic became the first glucagon-like peptide 1 (GLP-1) drug to receive the US Food and Drug Administrati...

Impressions : 950

Trump withdraws US from WHO; Novo’s Ozempic, Wegovy among 15 new drugs chosen for price negotiations under IRA

On the day Donald Trump was sworn in as the 47th President of the United States, there was a deluge of some 200 measures, which...

Impressions : 1597

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass